These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 10569498)

  • 41. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 Aug; 58(30):829-30. PubMed ID: 19661857
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains.
    Laassri M; Lottenbach K; Belshe R; Wolff M; Rennels M; Plotkin S; Chumakov K
    J Infect Dis; 2005 Dec; 192(12):2092-8. PubMed ID: 16288372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
    Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [End phase challenges of poliomyelitis eradication programme realization].
    Jarzabek Z
    Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.
    Guerra FA; Gress J; Werzberger A; Reisinger K; Walter E; Lakkis H; Grosso AD; Welebob C; Kuter BJ;
    Pediatr Infect Dis J; 2006 Oct; 25(10):912-9. PubMed ID: 17006287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Choice between inactivated and oral poliovirus vaccines in India.
    John TJ; Moore R; Gibson JJ
    Lancet; 1992 Feb; 339(8791):504. PubMed ID: 1346868
    [No Abstract]   [Full Text] [Related]  

  • 48. Update: availability of inactivated poliovirus vaccine--United States.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1994 Oct; 43(41):762-3. PubMed ID: 7935309
    [No Abstract]   [Full Text] [Related]  

  • 49. Polio control after certification: major issues outstanding.
    Fine PE; Oblapenko G; Sutter RW
    Bull World Health Organ; 2004 Jan; 82(1):47-52. PubMed ID: 15106300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polio immunization.
    Tulchinsky TH; Goldblum N
    N Engl J Med; 2001 Jan; 344(1):61-2; author reply 62-3. PubMed ID: 11187114
    [No Abstract]   [Full Text] [Related]  

  • 51. Stopping a polio outbreak in the post-eradication era.
    Fine PE; Sutter RW; Orenstein WA
    Dev Biol (Basel); 2001; 105():129-47; discussion 149-50. PubMed ID: 11763322
    [No Abstract]   [Full Text] [Related]  

  • 52. Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV).
    Rezapkin G; Dragunsky E; Chumakov K
    Biologicals; 2005 Mar; 33(1):17-27. PubMed ID: 15713553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epidemiology of poliomyelitis--options and update.
    Dutta A
    Vaccine; 2008 Oct; 26(45):5767-73. PubMed ID: 18755232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Eradication of polio by vaccination.
    Minor PD
    Virology; 2000 Mar; 268(2):231-2. PubMed ID: 10704330
    [No Abstract]   [Full Text] [Related]  

  • 56. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains.
    Minor PD; Dunn G; Ramsay ME; Brown D
    J Med Virol; 2005 Jan; 75(1):153-60. PubMed ID: 15543587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of a new combined vaccine in pediatric practices.
    Freed GL; Cowan AE; Clark SJ; Santoli J; Bradley J
    Pediatrics; 2006 Aug; 118(2):e251-7. PubMed ID: 16831895
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Food and Drug Administration. Tempest over polio vaccine.
    Anderson C
    Nature; 1991 Jun; 351(6327):510. PubMed ID: 2046758
    [No Abstract]   [Full Text] [Related]  

  • 59. Influence of the courts of law on biologicals development, regulation, and use.
    Curran WJ
    Bull World Health Organ; 1977; 55 Suppl 2(Suppl 2):53-65. PubMed ID: 305317
    [No Abstract]   [Full Text] [Related]  

  • 60. Some lots of "Salk" vaccine have lost potency.
    FDA Drug Bull; 1984 Dec; 14(3):22-3. PubMed ID: 6526170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.